Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2266 to 2280 of 7683 results

  1. Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]

    Awaiting development [GID-TA11336] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines ID6356

    Awaiting development [GID-TA11416] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Ranibizumab port delivery system for treating diabetic macular oedema ID6137

    Awaiting development [GID-TA11065] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency (MA review of TA963) [ID6426]

    Awaiting development [GID-TA11536] Expected publication date: 21 May 2025

    Technology appraisal guidance
    Awaiting development

  5. Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310]

    In development [GID-TA11504] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Human normal immunoglobulin for preventing infection in chronic lymphocytic leukaemia [ID6455]

      Status ...

    Technology appraisal guidance
    Topic selection

  7. Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]

    Awaiting development [GID-TA10757] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Artificial intelligence (AI)-derived software to help clinical decision making in stroke (DG57)

    Evidence-based recommendations on artificial intelligence-derived software to help clinical decision making in stroke

    Diagnostics guidance
    Last updated
    2 May 2024
    View recommendations

    Sections for DG57

  9. Cefepime–enmetazobactam for treating hospital-acquired pneumonia, including ventilator-associated pneumonia TS ID 12035

      Status ...

    Technology appraisal guidance
    Topic selection

  10. Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]

    In development [GID-TA11298] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Osimertinib for neoadjuvant treatment of EGFR mutation-positive resectable non-small-cell lung cancer ID 6472

    Awaiting development [GID-TA11589] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]

    Awaiting development [GID-TA10638] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Seladelpar for previously treated primary biliary cirrhosis ID 6429

    Awaiting development [GID-TA11609] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Imetelstat for treating intermediate-2 or high-risk relapsed or refractory myelofibrosis after a JAK inhibitor TS ID 8376

    Awaiting development [GID-TA11608] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis TS ID 12050

      Status ...

    Technology appraisal guidance
    Topic selection